2026

• business2026/02/16

  AskAt Terminates AAT-730 License Agreement Due to Breach by Oxford Cannabinoid Technologies Ltd.

  AskAt Inc. (Headquarters: Nagoya; President: Akihiro Furuta) announced today that it has terminated its license agreement with Oxford Cannabinoid Technologies Ltd. (“OCT”) regarding AAT-730, a CB2 agonist.
  The agreement, originally signed in September 2019, was terminated by AskAt due to a breach of contract by OCT.
  We will seek a new partner to continue the development.